Key Highlights

  • 10x Genomics shares fell 14.03% on October 30, 2026.
  • No company-specific news was identified for the session.
  • Illumina fell 18.6% after reporting a Revenue miss the same day.
  • Healthcare as a sector rose 0.45%, so the drop ran against the sector.

10x Genomics (NASDAQ:TXG) fell 14.03% on Friday in a session that was rough for both the broader market and life-science tools stocks. No company-specific news was found, and the most relevant context is what happened to a peer: Illumina (NASDAQ:ILMN) fell about 18.6% after reporting third-quarter revenue below estimates.

A Plausible but Unconfirmed Read-Through

When one company in an industry reports disappointing results, investors often reassess others in the same field, reasoning that customer spending patterns or Demand may affect peers too. That can pull down related stocks even when they have reported nothing new. Whether Illumina's shortfall reflects conditions that also apply to 10x Genomics is not established. Illumina's report said nothing directly about 10x Genomics, though the two share an investor base.

What 10x Genomics Does

The company makes instruments, consumables and software used by researchers to study biology at the level of single cells and to map gene activity within tissue, an area known as spatial biology. Customers are largely academic labs, research institutes and biopharma companies, which makes the Business sensitive to research funding. Stephens cut the stock to equal weight from overweight on October 23, a week before Friday's drop, and in its last reported quarter on August 6 the company beat revenue and Earnings estimates even though revenue was down from a year earlier.

Against a Rising Sector

The S&P 500 fell 140.32 points, or 1.8%, to 7,580.07 and the Nasdaq Composite dropped 747.73 points, or 2.9%, to 25,437.00, as Intel (NASDAQ:INTC)'s weak outlook triggered a chip rout and Amazon (NASDAQ:AMZN)'s results revived worries about AI spending. Health care rose 0.45% as investors rotated toward defensive areas, so the double-digit drop ran sharply against its sector. Twist Bioscience (NASDAQ:TWST) also fell in the same session.

The Company's Own Report Is Next

10x Genomics' next scheduled event is its third-quarter report in early November. Investors will look for consumables demand, instrument placements, commentary on academic and government research funding and any change to the full-year revenue outlook.